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Summary A multicentric, prospective phase IlIl study was carried out with the aim of testing the so-called 'worst drug rule' hypothesis, which
suggests the use of an effective but 'less active' regimen that first eradicates tumoral cells resistant to a second effective and 'more active'
regimen. With respect to this hypothesis, we considered the cisplatin plus vinorelbine regimen (CCDPNNR) as the more active regimen
compared with the non-cisplatin-containing regimen of ifosfamide plus high-dose epirubicin (IFO/EPI). Thus, a randomized study was carried
out to compare the sequencial strategy of three cycles of CDDPNNR followed by three cycles of IFO/EPI with the opposite sequence in
advanced non-small-cell lung cancer. A total of 100 consecutive previously untreated patients with stage III-IV non-small-cell lung cancer
were centrally randomized in two arms according to stage of disease and the performance status. Patients allocated to arm A received CDDP
(100 mg m-2 on day 1) plus VNR (25 mg m-2 i.v. on days 1 and 8) every 21 days for three cycles (step 1) followed, after restaging, by three
cycles of IFO (2.5 g m-2 with mesna on day 1) plus high-dose EPI (100 mg m-2 on day 1) every 21 days (step 2). Patients in arm B received
the opposite sequence. Type and rates of objective response were evaluated after step 1 and step 2 in agreement with WHO criteria and an
intent-to-treat analysis. Patients were also analysed fortoxicity patterns, time to progression and survival. After the first three cycles (step 1),
overall response rate (ORR), calculated according to an intent-to-treat analysis, was 47% and 21% for arm A and arm B respectively
(P= 0.0112). ORR for stage Ill patients was 55% and 14% for arm A and B respectively (P= 0.0097). In stage IV patients ORR was higher in
arm A than in arm B (42% vs 28%) but not statistically significant (P= 0.4). Clinical responses to the shift of chemotherapy (step 2) showed
that no patient pretreated with CDDPNNR and subsequently treated with IFO/EPI showed further response, whereas in the inverse sequence
arm CDDPNNR was able to induce 26% partial response (PR) rate in patients pretreated with IFO/EPI. This difference was statistically
significant (P= 0.037). The overall median time to progression (UTP) of arm A and arm B did not significantly differ (6 vs 4 months; P= 0.665).
However, median UTP of stage Ill patients was, respectively, 7 months for arm A and only 3 months for arm B. This difference was statistically
significant (P = 0.049). Median overall survival (OS) was 9 and 7 months respectively for arm A and arm B. Despite this trend the difference
was not significant (P = 0.328). Median OS of stage Ill patients showed a statistically significant advantage for arm A over arm B (13 vs 7
months, P= 0.03). In addition, no statistically significant difference in OS was recorded for stage IV patients (both arms 7 months, P= 0.526).
Our data do not confirm Day's 'worst drug rule' hypothesis, at least in patients with advanced non-small-cell lung cancer treated with the
above-mentioned regimens. The combination of CDDP and VNR seems more active, at least in terms of response rate, than the IFO/EPI,
which performed poorly.
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Until recently, only a few antineoplastic drugs have shown clinical Cullen, 1993; Crino et al, 1995; Thatcher et al, 1995) with a little
activity in excess of 15% overall response rate in advanced, stage impact on survival (Grilli et al, 1993; Non-Small Cell Lung
III-IV non-small-cell lung cancer (NSCLC). Of these drugs, Cancer Cooperative Group, 1995; Thatcher et al, 1995).
cisplatin (CDDP), vinblastine, vindesine, mitomycin C, etoposide, New antineoplastic drugs have recently become available for
and ifosfamide (IFO) have been the most widely used (Johnson, the treatment of NSCLC (Stewart and Dunlop, 1995; Thatcher et
1990; Lilenbaum and Green, 1993; Thatcher et al, 1995). To date, al, 1995). Among these agents, vinorelbine (Le Chevalier et al,
the bestcombinations ofthese drugs are able to yield a nearly 40% 1994), taxanes (Ettinger, 1993), and gemcitabine (Hansen and
overall response rate (ORR) (Joss et al, 1990; Sheperd et al, 1992; Lund, 1994) have been shown to be particularly active with
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acceptable toxicity. Moreover, older drugs have been used recently
in alternative ways that have improved clinical results: the use of
etoposide as chronic oral administration or ofhigh-dose epirubicin
(EPI) have produced interesting clinical results. In fact, although
EPI has been associated with a < 10% ORR when given as single
agent at conventional doses in advanced NSCLC (Joss et al, 1984;
Meyers et al, 1986), it may consistently yield a 20% ORR if used
at higher doses (. 100 mg/m2) (Wils et al, 1990; Martoni et al,
1991; Feld et al, 1992). For this reason high-dose EPI has also
been recently used in combination with CDDP in advanced
NSCLC with interesting results (Martoni et al, 1992).
The optimization of scheduling cancerchemotherapy has repre-
sented one of the most important goals for medical oncologists
since the elaboration of the alternating strategy of cancer
chemotherapy by Goldie and colleagues (1982). This strategy has
been tested in a few prospective studies with uncertain results
(Miller et al, 1986; Fukuoka et al, 1991; Weick et al, 1991).
A novel approach to chemotherapy scheduling is represented
by the so-called 'worst drug rule', which has been produced
by mathematical modelling starting from the limits of the
Goldie-Coldman model (Norton and Day, 1991). In cancer
chemotherapy, the most important cause of treatment failure is
represented by the high growth of drug-resistant neoplastic cells.
Therefore, if we take two active, potentially non-cross-resistant
treatments, but one 'more active' than the other, the critical point
is to kill tumoral cells resistant to the 'more active' therapy. This
end point might be theoretically reached using first the 'less
active' regimen, thus leading to the apparently paradoxical
hypothesis that the optimal chemotherapy schedule should use
more of the weaker treatment and/or use the less active therapy
first (Norton and Day, 1991).
With this rationale in mind, investigators from the Southern Italy
Oncology Group designed a phase HI trial to test this hypothesis,
considering CDDP-based regimens as the 'more active' ones than
the IFO-based regimens (without CDDP), which are effective but
'less active' (Gebbia et al, 1996). The combination of CDDP +
vinorelbine (VNR), which has been recently reported to be very
active in advanced NSCLC yielding a nearly 40% overall response
rate (Depierre et al, 1994; Gebbia et al, 1994; Le Chevalier et al,
1994), was chosen as the 'more active' treatment. Conversely the
regimen ofIFO 2.5 g m-2 onday 1-2 plus high-dose EPI 70 mg m-2
day 1, which has been reported to be quite effective in advanced
NSCLC (Brocato et al, 1995; Gridelli et al, 1996), was considered
as the 'less active' treatment. Thus a multicentric, prospective,
randomized study was carried out to compare the treatment
sequence of CDDP/VNR followed by IFO/EPI with the reverse
sequence to prove the hypothesis that the latter sequence is the
most active strategy according to Day's 'worstdrug rule' as it used
the 'less active' regimen first. Otheraims ofthe study included the
comparison ofthe CDDP+VNR regimen to the IFO+EPI regimen,
in terms ofboth response rates and patterns oftoxicity.
MATERIALS AND METHODS
Entry criteria and staging
Before entry into the study, patients had to fulfil all the following
eligibility criteria: histologically-confirmed diagnosis ofunresect-
able stage IIIAIIIB or metastatic stage IV NSCLC; measurable
disease according to the WHO criteria (Miller et al, 1981);
good performance status (Karnofsky index 2 80); age < 70 years;
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Arm A
CDDP 100 mg m-2 day 1 IFO 2.5 g m-2 days 1 and 2
x 3 or 4 cycles...> x3 or 4 cycles
VNR 25 mg m-2 days 1 and 8 EPI 100 mg m-2 day 1
Arm B
IFO2.5gm-2days1 and2 CDDP100mgm-2day1
x 3 or 4 cycles > x3 or 4 cycles
EPI 100 mg m-2 day 1 VNR 25 mg m-2 days 1 and 8
Figure 1 Treatment plan and study design
life-expectancy 2 3 months; no previous chemotherapy and/or
radiotherapy; absence of brain metastases; absence of second
malignancies with the exception of cutaneous basalioma or
adequately treated in situ uterine carcinoma; WBC . 4000 mm-',
PLT 2 120 000 mm-3, Hb 2 10 gr%; adequate liver (serum
bilirubin < 1.2 mg%, transaminases less than twice their normal
value) and renal functions (serum creatinine < 1.2 mg%; BUN
< 50 mg%, creatinine clearance < 60 ml/min); absence of uncon-
trolled severecardiovascular, metabolic, neurological orinfectious
diseases. Oral informed consent and geographical accessibility to
guarantee a correct follow-up were also necessary prerequisites.
The basal work-up included complete medical history and
physical examination, complete blood cell counts and serum
chemistries, standard 2p chest radiograph, abdominal sonogram,
99Tc bone scan, and ECG. All patients had also CT scan of the
thorax and the upperabdomen. Beforereceivinghigh-dose EPI, all
patients were given echocardiography with evaluation of the left
ventricular ejection fraction (LVEF). These procedures were
subsequently used for restaging and response assessment as
needed.
Study design and treatment plan
The main goal ofthe study was to analyse response rates, time to
progression (ITTP) and overall survival (OS) according to type of
treatment.
The study was divided in two steps (Figure 1). Eligible patients
were centrally randomized at the Oncological Institute, Bari, and
stratified according to stage (III vs IV) and performance status
(100-90 vs 80) (Stanley, 1980). The treatment plan was designed
as follows: patients in arm A received CDDP 100mgm-2 in
500 ml of normal saline during 1-h infusion with a standard pre-
and post-hydration protocol with magnesium sulphate and potas-
siumchloride supplements andforced diuresis with 250 ml of 18%
mannitol on day 1 plus VNR 25 mg m-2 i.v. bolus on days 1 and 8
every 3 weeks (step 1). This treatment was repeated every 21 days
for three cycles. Then patients were restaged and crossed, when
possible, to IFO 2.5 g m-2 in 1000 ml of normal saline over 2-h
infusion and uroprotection with mesna 800 mg i.v. at 0, 4, and 8 h
after IFO on days 1 and 2, plus EPI 100 mg m-2 i.v. bolus on day 1
(step 2). This treatment was repeated every 3 weeks for three
cycles. Patients in arm B received the opposite sequence: IFO plus
EPI (step 1) followed by CDDP plus VNR (step 2). In all groups
of patients, chemotherapy treatment was preceded by parenteral
administration of antiemetics, usually ondansetron 24 mg or
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granisetron 3 mg plus methylprednisolone 250 mg i.v., and
followed by an antiemetic protocol against delayed emesis.
Chemotherapy regimens were tentatively recycled every 3
weeks depending on toxicity. Dose adjustements were performed
according to toxicity. If mucositis of any grade, > grade 1
leucopenia and/or thrombocytopenia were present before recy-
cling, chemotherapy was delayed by 1 week, and drug dosages
reduced by 20% for the next cycles. The occurrence of grade 4
extrahaematological toxicity caused patients withdrawal from the
study. In case of a 15% reduction in LVEF chemotherapy treat-
ment was definitively stopped.
Patient selection was strictly controlled as the treatment plan
potentially included the delivery of six cycles of chemotherapy
that could represent an unrealistic goal in patients with poor
performance status at entry. The calculation of sample size was
based on a 25% difference between treatments. Thus, 102 patients
hadto be randomized todetect a 25% difference inresponse rate or
time to progression between two groups ofpatients at the signifi-
cance level ofa = 0.1 with an 80% power (p = 0.8).
Response evaluation
Objective responses were evaluated according to the WHO criteria
(Miller et al, 1981). ORR included both complete and partial
responses. Briefly, complete response (CR) was defined as the
complete disappearance ofall signs ofdisease for at least4 weeks;
a partial response (PR) was defined as a 2 50% reduction in the
sum of the products of the largest perpendicular diameters of
measurable lesions for at least 4 weeks without the appearance of
any new metastatic deposit or the increase in size of any pre-
existing lesion; stable disease (SD) as a < 50% decrease or < 25%
increase in the size of tumoral lesions; and progressive disease
(PD) as the appearance of any new lesions or a > 25% increase in
the size of tumour lesions. Any early death was considered as
treatment failure, and patients who received at least two cycles of
chemotherapy were considered evaluable for response analysis.
Statistics
Objective responses were reported as relative rates with their 95%
confidence limits (95% CL) according to an intent-to-treat
analysis. The chi-square test was applied to a contingency table
with the aim ofanalysing ifprognostic factors were well balanced
between arm A and arm B. Logistic linear analysis was carried out
to evaluate the effects of potential prognostic factors on response
rate. TTP was calculated from the first day of chemotherapy until
progressive disease was evidenced. OS was calculated from the
date of randomization until death or last follow-up. TTP and
survival curves were computer generated using the Kaplan-Meier
product-limit method and curve comparison was carried out by the
log-rank test. Toxicity of chemotherapy was carefully recorded
after every treatment cycle and graded according to the WHO
score system (Miller et al, 1981).
RESULTS
Patient population
From January 1994 to November 1995 100 consecutive, previ-
ously untreated eligible patients with stage III-IV NSCLC were
enrolled into the study. Accrual was stopped before reaching the
planned number of 102 cases because the previously established
enrollmentperiod was ended. Fifty-three patients were allocated in
arm A (53%) and 47 in arm B (47%). The main demographic and
clinical characteristics of enrolled patients according to stage of
disease and treatment arm are depicted in Table 1. Briefly, the two
arms were well balanced in terms of age and performance status
distribution, stage (III vs IV) and histological types, with no statis-
tically significant difference between any subgroup. The balance
of prognostic factors was good if patients were also analysed
within stages of disease. The majority of patients were men.
A 16% excess in the percentage of patients with performance
status (PS) 90/100 was observed for arm B over arm A among
stage IV patients, but this figure was not statistically significant
(P = 0.580). Squamous cell carcinomas represented the predomi-
nant histological subtype, but a 14% excess in the frequence of
adenocarcinomas was observed for arm B over arm A in stage IV
patients. Again, this difference was not statistically significant
(P = 0.567). In most cases, extrathoracic sites of disease included
bone, liver, adrenals and distant nodes. The frequency of
metastatic disease in the liver in arm A was double that in arm B.
Objective response
The first evaluation of types and rates of objective response was
carried out after the first three cycles of chemotherapy (step 1).
Types of objective response are depicted in Table 2. Response
rates were calculated according to an intent-to-treat analysis. ORR
was 47% (95% CL 33-61%) and 21% (95% CL 11-35%) for arm
A and arm B respectively. This difference was statistically signifi-
cant (P = 0.0112). Only one patient in each arm achieved a CR. If
response rates are analysed according to stage ofdisease, ORR for
stage III patients was 55% and 14%, respectively, for the
CDDP+VNR arm and the IFO+EPI arn with a strong statistically
significant difference in favour of arm A (P = 0.0097). Again, in
stage IV patients ORR was higher in arm A than in arm B (42% vs
28%) but this difference was not statistically significant (P = 0.4).
Overall, 43% ofpatients in arm A and 40% ofpatients in arm B
reached the second step of the study. Table 3 shows that the
reasons for withdrawal before reaching step 2 included drop in PS,
death, physician's decision to start locoregional therapy, refusal
and others. A higher proportion of patients treated initially with
IFO/EPI showed a drop in PS and could not reach step 2, and thus
were not crossed to CDDP/VNR. A higher percentage of patients
treated initially with CDDP/VNR underwent locoregional therapy
and were subsequently shown to have a longer survival.
Clinical responses to the shift of chemotherapy (step 2) are
depicted in Table 4. Nopatientpretreated withCDDP/VNR (step 1)
and subsequently treated with IFO/EPI showed further objective
response, whereas in the inverse sequence arm CDDP/VNR was
able to induce a 26% PR rate in patients pretreated with IFO/EPI.
This difference was statistically significant (P = 0.037).
Table 5 depicts the effects of shifting chemotherapy on the
degree of objective response. In other words, if shifting
chemotherapy could improve SD to PR or, for instance, a 50%
PR to a 75% PR. Although 35% of patients pretreated with
CDDPNNR showed an improvement in the degree of PR
achieved after the IFO/EPI regimen, however this rate increased to
83% for the opposite sequence.
Among patients who completed the full chemotherapy plan,
6 out of 23 patients (26%) in arm A underwent radiotherapy,
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Table 1 Patients' characteristics
Arm A Arm B
Clinical data Stage IlIl Stage IV Stage IlIl Stage IV
Number of enrolled patients 22 (100%) 31 (100%) 22 (100%) 25 (100%)
Sex
Male 20 (91%) 26 (84%) 21 (95%) 19 (76%)
Female 2 (9%) 5 (16%) 1 (5%) 6 (24%)
Age
Median 64.5 61.0 64.0 62.0
Range 48-70 41-70 51-70 28-69
PS
Median 90 90 90 90
Range 80-100 80-100 80-100 80-100
PS 90-100 15 (68%) 16 (52%) 14 (64%) 17 (68%)
PS 80 7 (32%) 15 (48%) 8 (36%) 8 (32%)
Histology
Squamous 15 (68%) 15 (48%) 13 (59%) 6 (24%)
Adenocarcinoma 5 (22%) 13 (42%) 6 (27%) 14 (56%)
Large cell 1 (05%) 1 (03%) 1 (5%) 2 (8%)
Anaplastic 1 (05%) 2 (07%) 2 (9%) 3 (12%)
Site of diseasea
Locoregional 25 22
Local recurrence 4 1
Lung (metastasis) 7 9
Bone 14 12
Liver 12 6
Adrenals 4 2
Skin 2 2
Soft tissue 1 0
Node (extrathoracic) 3 2
a Sites of disease are reported only for stage IV patients. No statistically significant differences in clinical data were observed between
the four groups of patients.
Table 2 Response rates according to treatment arm and stage (step 1)
Objective response
Overall Complete Partial Stable Progression
All patients
Arm A (step 1)
CDDPNNR 25 (47%) 1 (2%) 24 (45%) 9 (17%) 19 (36%)
Arm B (step 1)
IFO/EPI 10 (21%) 1 (2%) 9 (195) 12 (26%) 25 (53%)
P= 0.0112 (Fisher's exact test)
Stage Ill
Arm A (step 1)
CDDPNNR 12 (55%) 1 (5%) 11 (50%) 4 (18%) 6 (27%)
Arm B (step 1)
IFO/EPI 3 (14%) 0(H) 3 (14%) 6 (27%) 13 (59%)
P = 0.0097 (Fisher's exact test)
Stage IV
Arm A (step 1)
CDDPNNR 13 (42%) 0 (-) 13 (42%) 5 (16%) 13 (42%)
Arm B (step 1)
IFO/EPI 7 (28%) 1 (4%) 6 (24%) 5 (20%) 13 (52%)
P = 0.4 (Fisher's exact test)
Response rates were calculated according to an intent-to-treat analysis.
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Table 3 Reasons for stopping treatment before shift to step 2
Arm A Arm B
CDDPNNR -e IFO/EPI IFO/EPI -* CDDPNNR
Number of patients who reached step 11 23/53 (43%) 19/47 (40%)
Patients who did not reach step 11 30/53 (57%) 28/47 (60%)
Drop pSa 13/30 (43%) 16/28 (57%)*
Deathb 4/30 (13%) 4/28 (14%)
Locoregional treatmentc 6/30 (20%) 2/28 (7%)t'
Toxicityd 4/30 (13%) 1/28 (4%)
Other 3/30 (10%) 3/28 (11%)
Too early 0/30 2/28 (7%)
aAssociated with progressive cancer, or occurrence of brain metastases, or cancer-related
complications; bnot treatment related; ceither palliative or curative; dtoxicity includes myelosuppression,
neurotoxicity and renal toxicity; *P= 0.43 (NS); P= 0.25 (Fisher's exact test);
P< 0.0001 (McNemar's test).
Table 4 Objective response to chemotherapy after step 2
Arm A Arm B
Step 1 Step 2 Step 1 Step 2
CDDPNNR -> IFO/EPI IFO/EPI -* CDDPNNR
Patients who completed step 2 23 (100%) 19 (100%)
Overall response 0 5 (26%)'
Complete response 0 1 (5%)
Partial response 0 4 (21%)
Non-response 23 (100%) 14 (74%)
(SD or PD)
*P = 0.037 (Fisher's exact test).
Table 5 Improvement of type and degree of objective response after step 2
Arms Step I Step II
Arm A
CDDPNNR -* IFO/EPI 17 PR > 50% -e 6 PR > 75% (35%)
Arm B
IFO/EPI -> CDDPNNR 6 PR > 50% -e 5 PR > 75% (83%)
P = 0.06 (Fisher's exact test).
whereas 4 out of 14 patients (28%) in arm B received radiation
therapy. This difference was not statistically significant.
Time to progression and survival
The overall median TTP was 6 and 4 months for arm A and arm B
respectively (Figure 2). These figures did not significantly differ
when statistical analysis was performed (P = 0.665). Median TTP
ofstage III patients was, respectively, 7 months for arm A andonly
3 months for arm B (Figure 3). This difference, although weak,
was statistically significant (P = 0.049). In stage IV patients,
median TTP was 6 and 5 months, respectively, for arm A and arm
B. This difference was not statistically significant (P = 0.708).
Figure 4 median OS was 9 and 7 months, respectively, for arm A
and arm B. Despite this trend, the difference in median OS was not
statistically significant (P = 0.328). In addition, median OS for
stage III patients showed a statistically significant advantage for
arm A overarm B (13 months vs 7 months, P =0.03) (Figure5). No
statistically significant difference in OS was recorded for stage IV
patients (both arms 7 months; P = 0.526). Median TTP and OS for
patients who completed step 1 + 2 showed no statistically signifi-
cant difference between the two arms. Median TTP and OS of
patients who achieved a major objective response and completed
both treatment steps were also notstatistically different (P =0.320).
Toxicity
Haematological and non-haematological toxicities are depicted in
Tables 6 and 7 respectively. The two regimens CDDP+VNR and
IFO+EPI were almost equitoxic with the exception of grade 3/4
leucopenia, which was statistically more frequent during the
administration ofthe IFO+EPIregimen, andoftransientperipheral
neurotoxicity, which was more frequent for the CDDPNVNR
regimen. Toxicity pattern and severity of side-effects were
not related to timing and/or sequence of chemotherapy
(CDDP/VNR-*IFO/EPI equals the opposite sequence). Of note,
was the incidence of red blood cell toxicity in all arms. On
average, anaemia was recorded in almost 40% ofcases.
Overall, dose reduction was performed in 11.7% of cycles
because of toxicity. Dose reduction was because of mucositis and
myelosuppression in patients treated with the IFO/EPI regimen,
and to neurological and renal toxicity in patients treated with the
CDDP/VNR regimen.
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DISCUSSION
This paper reports the results of a prospective, randomized phase
III study carried out with the aims of (a) testing Day's hypothesis
ofthe 'worst drug rule'; (b) evaluating the activity oftwo different
combination regimens (CDDPNNR vs IFO/EPI) at least in
terms of response rates; and (c) investigating the possibility of
improving response rate or type of response crossing the two
regimens after the first three cycles ofchemotherapy.
In 1982 Goldie and colleagues elaborated a mathematical model
of cancer chemotherapy scheduling based on the hypothesis that
alternating non-cross-resistant multidrug regimens could maxi-
mize the probability of eliminating tumour cells resistant to both
treatments improving ultimately the clinical outcome of cancer
patients. This hypothesis was initially supported by a phase Ill
clinical trial carried out by the Southwest Oncology Group in
which alternating combination chemotherapy was superior to stan-
dard therapy in terms of duration of response and survival (Miller
et al, 1986). This hypothesis, however, was not subsequently
confirmed in two other prospective studies (Fukuoka et al, 1991;
Weick et al, 1991).
Figure 5 Survival stage Ill. *, Arm A; *, arm B
Starting within the limits of the Goldie-Coldman model, Day
elaborated a new chemotherapy scheduling hypothesis based on
the recognition ofhigh growth ofresistant neoplastic cells as the
leading cause of cancer treatment failure. If we take two effec-
tive, but non-equi-active, non-cross-resistant regimens, the best
schedule to achieve optimal cell kill would, paradoxically,
consider first the use of the less active treatment to eradicate
cells potentially resistant to the more active treatment, and then
to give the more active chemotherapeutic regimen (Norton and
Day, 1991).
Chemotherapy regimens containing cisplatin usually produce
the best clinical results at least in terms of response rate, whereas
regimens without cisplatin are usually associated with low
response rate (Thatcher et al, 1995; Carney 1996). Trials using
ifosfamide plus vinca alkaloids have obtained response rates in the
range of 20-30%, far lower than that reported for cisplatin-based
regimens (Drings et al, 1989; Gebbia et al, 1996). Thus, consid-
ering CDDP-based regimens as 'more active' than the IFO-based
combinations, the administration of IFO/EPI followed by
CDDPNNR (arm B) should have given better results than the
opposite sequence (arm A). However, in our study on statistically
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Table 6 Haematological toxicity according to regimen and sequence.
Step 1 Step 2
Type oftoxicity CDDPNNR IFO/EPI CDDPNNR IFO/EPI
Number of patients 52 (100%) 47 (100%) 23 (100%) 19 (100%)
WBC 28 (54%) 21 (45%) 10 (43%) 14 (74%)
G1/2 26 (50%) 11 (23%) 9 (49%) 08 (42%)
G3/4 2 (4%) 10 (21%) 1 (4%) 06 (31%)
P= 0.012 P= 0.034
PLT 7 (14%) 8 (17%) 5 (21%) 04 (28%)
G1/2 7 (14%) 7 (15%) 4 (17%) 03 (16%)
G3/4 0 1 (2%) 1 (4%) 01 (05%)
P=NS P=NS
Hb 24 (46%) 15 (32%) 10 (43%) 13 (68%)
G1/2 19 (36%) 13 (28%) 6 (26%) 10 (52%)
G3/4 5 (10%) 2 (4%) 4 (17%) 03 (16%)
P= NS trend P=NS
Table 7 Non-haematological toxicity according to regimen and sequence (WHO score)
Step 1 Step 2
Type oftoxicity CDDPNNR IFO/EPI CDDPNNR IFO/EPI
Number of patients 52 (100%) 47 (100%) 23 (100%) 19 (100%)
Nausea vomiting 35 (68%) 27 (57%) 17 (74%) 14 (74%)
G1/2 30 (58%) 20 (42%) 10 (43%) 12 (63%)
G3/4 5 (10%) 7 (15%) 7 (31%) 2 (10%)
P=NS P=NS
Stomatitis 12 (23%) 16 (34%) 4 (17%) 7 (36%)
G1/2 12 (23%) 14 (30%) 4 (17%) 5 (26%)
G3/4 0 2 (4%) 0 2 (10%)
P=NS P=NS
Diarrhoea 3 (6%) 5 (11%) 2 (9%) 4 (21%)
G1/2 2 (4%) 4 (9%) 2 (9%) 3 (16%)
G3/4 1 (2%) 1 (2%) 0 1 (5%)
P=NS P=NS
Neurological 8 (15%)* 0 8 (35%)* 1 (5%)
G1/2 8 (15%) 0 8 (35%) 1 (5%)
P= 0.006 P= 0.027
Renal 5 (20%) 1 (2%) 5 (22%) 2 (10%)
G1/2 5 (20%) 1 (2%) 5 (22%) 2 (10%)
P=NS P=NS
Cardiac 2 (4%) 2 (4%) 0 0
P= NS
significant difference in median TTP between the two treatment
arms could be demonstrated (arm A 6 months vs arm B 4 months),
with the exception of a weak difference in favour of the
CDDPNVNR-IFO/EPI sequence in stage III patients (7 vs 3
months). Moreover, no statistically significant difference in OS
was recorded between arm A and B (9 vs 7 months), with the
notable exception of stage III patients treated with CDDP/VNR-+
IFO/EPI sequence, which showed a statistically significant longer
median OS over the opposite schedule (13 vs 7 months). These
figures concerning overall survival are in the range reported in
medical literature (Thatcher et al, 1995). Thus Day's hypothesis of
the 'worst drug rule' is not confirmed by this study as no statisti-
cally significant difference in TTP and OS was recorded between
the two arms. In contrast, the CDDP/VNR-*IFO/EPI schedule
was superior to the opposite sequence compared with the objective
response rate in all stages and in terms ofTTP in stage IIIpatients.
The results achieved in our study demonstrate that the
CDDP/VNR combination is superior in terms of objective
response rate to the IFO/EPI regimen as front-line therapy as
evidenced by the clinical evaluation performed after the first three
cycles ofchemotherapy. In step 1 ORR was statistically higher for
the CDDPIVNR arm than for the IFO/EPI arm (47% vs 21%;
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P = 0.0122). This trend was especially true for stage III patients
(55% vs 14% ORR; P = 0.0097) and less evident for patients with
stage IV disease (42% vs 28%). As a consequence, a higher
number of patients treated initially with IFO/EPI showed a drop,
often because of progressive disease, in performance status and
could not reach step 2. Data achieved from evaluation performed
after step 2 demonstrated that the CDDPNVNR regimen was
significantly superior in cross-over analysis than the IFO/EPI
combination in terms of ORR and amelioration of already
obtained PR. No patient pretreated with CDDP/VNR and subse-
quently treated with IFO/EPI showed further objective response,
whereas in the inverse sequence CDDP/VNR was able to induce
26% PR rate in patients previously treated with the IFO/EPI
regimen. Moreover, whereas 35% of patients pretreated with
CDDP/VNR showed an amelioration of PR after IFO/EPI, this
rate increases to 83% for the opposite sequence.
Clinical results concerning the efficacy of the CDDP/VNR
regimen in terms of objective response rate are in the range of
activity reported in medical literature by other investigators with
the same combination (Depierre et al, 1994; Le Chevalier et al,
1994) or with other CDDP-based polychemotherapeutic regimens
(Joss et al, 1990; Martoni et al, 1992; Sheperd et al, 1992; Cullen,
1993; Crino et al, 1995; Thatcher et al, 1995). However, figures
obtained in the present study with the combination of IFO and
high-dose EPI are strikingly lower than those previously reported
(De Marinis et al, 1990; Brocato et al, 1995; Gridelli et al, 1996)
despite careful selection ofpatients with good performance status.
The two regimens were safely administered on an out-patient basis
and were relatively well tolerated. The two combinations were
equitoxic with the exception of grade 3/4 leucopenia, which was
statistically more frequent forIFO/EPI and ofneurotoxicity, which
was more frequent for CDDP/VNR. Toxicity pattern and severity
were independent of timing and sequence. Of note, was the
incidence ofRBC toxicity in all arms.
In conclusion, the above-mentioned data do not support Day's
'worst drug rule', at least using these regimens in stage III-IV
NSCLC. No survival benefit could be demonstrated using first the
'less active' regimen. Combination chemotherapy using IFO and
high-dose EPI is less effective than the CDDP/VNR regimen in
inducing objective response in patients with advanced NSCLC.
This observation may explain, at least in part, the failure of the
'worst drug rule' in this trial. In fact, the suboptimal activity ofthe
IFO/EPI regimen in a very aggressive disease as NSCLC is not
sufficient to induce an objective remission in most patients, a high
proportion ofwhom will soon show progressive disease that is less
amenable with chemotherapy even with acisplatin-based regimen.
Further efforts should be made in the future to improve the
outcome ofpatients with advanced NSCLC.
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